Integer Holdings Corporation $ITGR Shares Purchased by Intech Investment Management LLC

Intech Investment Management LLC raised its holdings in Integer Holdings Corporation (NYSE:ITGR) by 92.8% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 22,682 shares of the medical equipment provider’s stock after purchasing an additional 10,915 shares during the period. Intech Investment Management LLC owned about 0.07% of Integer worth $2,677,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the business. AdvisorNet Financial Inc acquired a new position in Integer during the first quarter worth $28,000. Opal Wealth Advisors LLC acquired a new position in Integer during the first quarter worth $28,000. Bessemer Group Inc. boosted its stake in Integer by 73.1% during the first quarter. Bessemer Group Inc. now owns 296 shares of the medical equipment provider’s stock worth $35,000 after buying an additional 125 shares during the last quarter. SVB Wealth LLC acquired a new position in Integer during the first quarter worth $35,000. Finally, Headlands Technologies LLC boosted its stake in Integer by 1,234.8% during the first quarter. Headlands Technologies LLC now owns 1,228 shares of the medical equipment provider’s stock worth $145,000 after buying an additional 1,136 shares during the last quarter. 99.29% of the stock is owned by institutional investors and hedge funds.

Integer Stock Performance

Integer stock opened at $101.53 on Monday. The company has a debt-to-equity ratio of 0.72, a quick ratio of 2.18 and a current ratio of 3.41. The stock has a fifty day moving average of $109.53 and a two-hundred day moving average of $115.83. The company has a market capitalization of $3.56 billion, a price-to-earnings ratio of 44.73, a PEG ratio of 0.80 and a beta of 1.03. Integer Holdings Corporation has a fifty-two week low of $100.89 and a fifty-two week high of $146.36.

Integer (NYSE:ITGR) last posted its quarterly earnings data on Thursday, July 24th. The medical equipment provider reported $1.55 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.57 by ($0.02). Integer had a return on equity of 12.27% and a net margin of 4.61%.The business had revenue of $476.00 million for the quarter, compared to analyst estimates of $464.37 million. During the same quarter last year, the business earned $1.30 EPS. Integer’s revenue for the quarter was up 11.4% compared to the same quarter last year. Integer has set its FY 2025 guidance at 6.250-6.510 EPS. On average, analysts anticipate that Integer Holdings Corporation will post 6.01 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on ITGR. Truist Financial cut their price objective on Integer from $145.00 to $137.00 and set a “buy” rating on the stock in a report on Friday, July 25th. Wall Street Zen raised Integer from a “hold” rating to a “buy” rating in a research report on Saturday, August 30th. Citigroup raised Integer from a “hold” rating to a “strong-buy” rating and upped their target price for the company from $133.00 to $140.00 in a research report on Thursday, May 22nd. Raymond James Financial reduced their price objective on Integer from $150.00 to $143.00 and set an “outperform” rating for the company in a research note on Friday, July 25th. Finally, Wells Fargo & Company reduced their price objective on Integer from $152.00 to $132.00 and set an “overweight” rating for the company in a research note on Friday, July 25th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $140.25.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.